UNITY BIOTECHNOLOGY INC (UBX)
US91381U2006 - Common Stock
Taking everything into account, UBX scores 3 out of 10 in our fundamental rating. UBX was compared to 588 industry peers in the Biotechnology industry. UBX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. UBX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year UBX has reported negative net income.
In the past year UBX has reported a negative cash flow from operations.
UBX had negative earnings in each of the past 5 years.
UBX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
UBX has a worse Return On Assets (-75.82%) than 69.23% of its industry peers.
With a Return On Equity value of -145.14%, UBX is not doing good in the industry: 64.79% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -75.82% | ||
| ROE | -145.14% | ||
| ROIC | N/A |
ROA(3y)-52.3%
ROA(5y)-50.68%
ROE(3y)-101.6%
ROE(5y)-84.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for UBX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
UBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
UBX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for UBX has been increased compared to 5 years ago.
Compared to 1 year ago, UBX has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -11.08, we must say that UBX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -11.08, UBX is not doing good in the industry: 78.80% of the companies in the same industry are doing better.
There is no outstanding debt for UBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.08 |
ROIC/WACCN/A
WACC8.83%
2.3 Liquidity
A Current Ratio of 5.76 indicates that UBX has no problem at all paying its short term obligations.
UBX's Current ratio of 5.76 is fine compared to the rest of the industry. UBX outperforms 60.68% of its industry peers.
UBX has a Quick Ratio of 5.76. This indicates that UBX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.76, UBX is in the better half of the industry, outperforming 61.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.76 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 58.40% over the past year.
Looking at the last year, UBX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
Measured over the past years, UBX shows a very negative growth in Revenue. The Revenue has been decreasing by -29.52% on average per year.
EPS 1Y (TTM)58.4%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q51.47%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y-29.52%
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 14.46% on average over the next years. This is quite good.
Based on estimates for the next years, UBX will show a very strong growth in Revenue. The Revenue will grow by 210.67% on average per year.
EPS Next Y53.48%
EPS Next 2Y26.97%
EPS Next 3Y18.65%
EPS Next 5Y14.46%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y293.23%
Revenue Next 5Y210.67%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
UBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year UBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as UBX's earnings are expected to grow with 18.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.97%
EPS Next 3Y18.65%
5. Dividend
5.1 Amount
UBX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
UNITY BIOTECHNOLOGY INC
NASDAQ:UBX (4/19/2024, 7:21:24 PM)
After market: 1.51 +0.01 (+0.67%)1.5
-0.01 (-0.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap25.17M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -75.82% | ||
| ROE | -145.14% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.76 | ||
| Quick Ratio | 5.76 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)58.4%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y53.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y